SHPH - MCAP CO - Shuttle Pharmaceuticals

Shuttle Pharmaceuticals (SHPH) specializes in developing adjuvant agents to enhance brain tumor radiation, which guarantees the company exclusive pricing power. The daily price action, currently trading at 0.02, correlates with a dependence on grants and the high risks associated with its clinical portfolio. Meanwhile, the business relies on strict research bioethics and the eco-friendly processing of laboratory waste.

Shuttle Pharmaceuticals (SHPH) develops radiosensitizers for cancer therapy without having FDA-approved products or established market pricing. Under these conditions, the company's market capitalization reflects the speculative value of future intellectual property rather than current revenue. This metric is calculated as the product of the current share price and the total number of outstanding securities. The indicator measures aggregate market demand, determining the scale of the business in the eyes of investors. The market capitalization trend visualizes the level of confidence in the success of clinical trials.